Journal article

Cost-effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression

Pedro Aguiar, Luke A Perry, Gilberto L Lopes

LUNG CANCER MANAGEMENT | FUTURE MEDICINE LTD | Published : 2016

DOI: 10.2217/lmt-2016-0016

University of Melbourne Researchers

Citation metrics

5Web of Science
8Dimensions

Keywords

Nivolumab
Lung Cancer
Metaanalysis
Docetaxel
Outcomes
Predictive Biomarker
Life Sciences & Biomedicine
Cost-Effectiveness
Respiratory System
Health Technology Assessment
Cost–effectiveness
Cell Lung-Cancer
Science & Technology
Immunotherapy